Last update 21 Nov 2024
Insulin aspart (Huisheng Biological)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Biosimilar, Hormone |
Synonyms Insulin aspart Biosimilar (Jilin Huisheng Biological Pharmaceutical Co., Ltd.), Insulin aspart(Jilin Jinsheng Pharmaceutical Co. Ltd.), 门冬胰岛素30注射液 (吉林津升制药) + [1] |
Target |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (26 Dec 2023), |
Regulation- |
Login to view timeline
Gene Sequence
Sequence Code 4857
The sequence is quoted from: *****
Sequence Code 31953
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Insulin aspart (Huisheng Biological)门冬胰岛素30注射液与诺和锐30在健康人体的药代动力学和药效动力学的比对研究
[Translation] Comparative study on the pharmacokinetics and pharmacodynamics of insulin aspart 30 injection and NovoRapid 30 in healthy volunteers
门冬胰岛素注射液在中国健康受试者中的随机、开放、单剂量、2制剂、2周期、2序列、双交叉生物等效性试验研究
[Translation] A randomized, open-label, single-dose, two-formulation, two-cycle, two-sequence, double-crossover bioequivalence study of insulin aspart injection in Chinese healthy subjects
多中心、随机、开放、平行分组、阳性药对照评价门冬胰岛素30注射液与二甲双胍联合治疗口服降糖药控制不佳的2型糖尿病的有效性和安全性研究
[Translation] A multicenter, randomized, open, parallel-group, positive-control study to evaluate the efficacy and safety of insulin aspart 30 injection combined with metformin in the treatment of type 2 diabetes that is poorly controlled by oral hypoglycemic drugs
100 Clinical Results associated with Insulin aspart (Huisheng Biological)
Login to view more data
100 Translational Medicine associated with Insulin aspart (Huisheng Biological)
Login to view more data
100 Patents (Medical) associated with Insulin aspart (Huisheng Biological)
Login to view more data
100 Deals associated with Insulin aspart (Huisheng Biological)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus | CN | 26 Dec 2023 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | NDA/BLA | CN | 16 Apr 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free